Dexrazoxane Prevents Anthracycline-Related Cardiotoxicity in Childhood AML
- OPACC
- Apr 30, 2020
- 1 min read
New data from researchers at the Children’s Hospital of Philadelphia (CHOP) suggests use of dexrazoxane could provide some much-needed cardiovascular protection to pediatric patients undergoing chemotherapy for acute myeloid leukemia (AML).
Comments